Primecap Management Co. CA Sells 35,000 Shares of Edwards Lifesciences Co. (NYSE:EW)

Primecap Management Co. CA decreased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 1.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,901,000 shares of the medical research company’s stock after selling 35,000 shares during the quarter. Primecap Management Co. CA owned 0.31% of Edwards Lifesciences worth $144,951,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Martin Capital Advisors LLP lifted its position in shares of Edwards Lifesciences by 0.5% during the 4th quarter. Martin Capital Advisors LLP now owns 25,490 shares of the medical research company’s stock worth $1,944,000 after buying an additional 128 shares in the last quarter. Legacy Wealth Asset Management LLC lifted its position in shares of Edwards Lifesciences by 0.8% during the 4th quarter. Legacy Wealth Asset Management LLC now owns 16,958 shares of the medical research company’s stock worth $1,293,000 after buying an additional 134 shares in the last quarter. Johnson Financial Group Inc. lifted its position in shares of Edwards Lifesciences by 23.0% during the 4th quarter. Johnson Financial Group Inc. now owns 771 shares of the medical research company’s stock worth $59,000 after buying an additional 144 shares in the last quarter. DMC Group LLC lifted its position in shares of Edwards Lifesciences by 4.5% during the 4th quarter. DMC Group LLC now owns 3,561 shares of the medical research company’s stock worth $272,000 after buying an additional 154 shares in the last quarter. Finally, Granite Harbor Advisors Inc. lifted its position in shares of Edwards Lifesciences by 4.2% during the 3rd quarter. Granite Harbor Advisors Inc. now owns 3,832 shares of the medical research company’s stock worth $265,000 after buying an additional 155 shares in the last quarter. Institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total value of $1,212,624.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares in the company, valued at $14,639,824.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, VP Jean-Luc M. Lemercier sold 14,400 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $84.21, for a total value of $1,212,624.00. Following the completion of the transaction, the vice president now directly owns 173,849 shares in the company, valued at $14,639,824.29. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $85.59, for a total transaction of $620,955.45. Following the completion of the transaction, the chief financial officer now owns 19,074 shares of the company’s stock, valued at $1,632,543.66. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 180,707 shares of company stock worth $16,034,814. Corporate insiders own 1.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the stock. Evercore ISI lowered their price target on shares of Edwards Lifesciences from $92.00 to $89.00 and set an “in-line” rating on the stock in a report on Friday, April 26th. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the stock a “hold” rating in a report on Friday, April 26th. Royal Bank of Canada lifted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the stock an “outperform” rating in a report on Monday, April 15th. Morgan Stanley lifted their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a report on Thursday, March 21st. Finally, Oppenheimer lifted their price target on shares of Edwards Lifesciences from $93.00 to $100.00 and gave the stock an “outperform” rating in a report on Monday, March 18th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $94.31.

Edwards Lifesciences Price Performance

Shares of EW traded up $0.52 during mid-day trading on Friday, reaching $87.98. 1,786,623 shares of the stock traded hands, compared to its average volume of 2,524,065. The firm has a fifty day moving average price of $89.68 and a 200 day moving average price of $81.63. The company has a market cap of $53.02 billion, a price-to-earnings ratio of 37.92, a price-to-earnings-growth ratio of 3.20 and a beta of 1.10. The company has a current ratio of 3.75, a quick ratio of 2.67 and a debt-to-equity ratio of 0.08. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, beating analysts’ consensus estimates of $0.64 by $0.02. The firm had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.58 billion. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. As a group, equities research analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.